In summary, our data indicate that the miR-29b-3p/HMGB1/TLR4/NF-κB signaling pathway might be essential for liver fibrosis and that CA could be a promising therapeutic agent in liver fibrosis by modulating the miR-29b-3p/HMGB1/TLR4 signaling pathway. This evidence concerns the gene NFKB1 and Hepatic fibrosis.